Table 1.

Urinary exosomal miRNAs differentially expressed between metastatic and localized PCa.

	Discovery set				Validation set (qRT-PCR)		Combined: model construction set (qRT-PCR)
	Discovery (TLDA)		Technical validation (qRT-PCR)
miRNA	Fold change	p-value	Fold change	p-value	Fold change	p-value	Fold change	p-value
miR-636	0.33	0.039	0.82	0.582	0.44	0.013	0.53	0.004
miR-140-3p	2.17	0.017	2.62	0.005	1.76	0.137	1.19	0.424
miR-21	3.15	0.005	2.95	0.003	2.56	0.044	2.20	0.006
miR-16	2.92	0.050	3.31	0.006	1.98	0.190	2.12	0.010
miR-142-3p	4.33	0.002	11.7	7.92 × 10−6	4.83	0.206	3.20	0.021
miR-451	3.88	0.049	8.42	0.003	3.84	0.008	6.31	2.12 × 10−6

Statistically significant differences (P < 0.05) are in bold.

Discovery set: 42 PCa patients (19 localized and 23 metastatic).

Validation set: 70 PCa patients (56 localized and 14 metastatic).

Model construction set (Combined/qRT-PCR): 112 PCa patients (75 localized and 37 metastatic).

TLDA TaqMan low-density miRNA array, qRT-PCR quantitative reverse transcription–polymerase chain reaction.